ArticleJournal of investigative medicine high impact case reports
Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management.
Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Revisiting Secondary Dilative Cardiomyopathy.International journal of molecular sciences · 2025Pooled it
- Brazilian Society of Cardiology Guideline on Myocarditis - 2022.Arquivos brasileiros de cardiologia · 2022Guideline
- Pooled it
- The gut-heart axis in cardio-oncology.Cardiovascular research · 2026Review
- Super-Refractory Status Epilepticus (SRSE) in a Patient With Compound Heterozygous OPA1 Variants: Case Report and Literature Review.Annals of clinical and translational neurology · 2026Review
- Successful Treatment of Chronic Active Epstein-Barr Virus Infection Complicated by Cardiomyopathy in an Adult Patient.Internal medicine (Tokyo, Japan) · 2026Article
- Ameliorative effects of Spirulina platensis niosome and Echinacea purpura on cyclophosphamide-induced splenic, cardiac and neurotoxicity via modulating NF-κB pathway and oxidative stress.Scientific reports · 2026Article
- Early electrocardiographic changes associated with anticancer chemotherapy in a Sub-Saharan African population: a prospective cohort study.BMC cancer · 2026Article
- Caught in the crossfire: cardiac complications of cancer therapy.The Journal of clinical investigation · 2026Review
- Chemotherapy-associated coronary thrombosis presenting as acute coronary syndrome in breast cancer: a case report.BMC cardiovascular disorders · 2026Article
- The Regulatory Landscape of Ferroptosis and Iron Homeostasis: Pathophysiological Mechanisms and Therapeutic Horizons in Cardiovascular Disease.Drug design, development and therapy · 2026Review
- MiRNA Regulations in Cardiotoxicity Induced by Oncologic Therapies and Possible Immune Response.Current medicinal chemistry · 2026Review
- Cardiotoxicity in breast cancer patients treated with chemoradiotherapy.Exploration of targeted anti-tumor therapy · 2026Review
- The utility of novel echocardiographic techniques in evaluating cardiac function in patients undergoing hematopoietic stem cell transplantation: a pilot study.Scientific reports · 2025Article
- Cardio-Oncology and Multi-Imaging Modalities.Journal of clinical medicine · 2025Review
- Chrysin mitigates cyclophosphamide-triggered cardiotoxicity in rats: Insights into cardioprotection via Treg expression modulation and iNOS downregulation.Toxicology reports · 2025Article
- A breast cancer patient with chemotherapy-induced chronic lymphocytic myocarditis successfully treated with steroid therapy.Journal of cardiology cases · 2025Article
- Solid tumour cellular therapy - principles of toxicity management.Immuno-oncology technology · 2025Review
- The mitigatory capabilities of exercise on breast cancer chemotherapy-induced cardiotoxicity.Frontiers in cell and developmental biology · 2025Review
- Management of a Patient with Cardiovascular Disease Should Include Assessment of Primary and Secondary Immunodeficiencies: Part 2-Secondary Immunodeficiencies.Healthcare (Basel, Switzerland) · 2024Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclophosphamide is increasingly used to treat various types of cancers and autoimmune conditions. Higher doses of this drug may produce significant cardiac toxicity, including fatal hemorrhagic myocarditis. In this review, we present a case of cyclophosphamide-induced cardiomyopathy requiring mechanical circulatory support. We also describe the pathophysiology, clinical manifestations, and risk factors for this important clinical entity and propose early detection and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.